Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
J Reprod Med
; 61(3-4): 159-62, 2016.
Article
em En
| MEDLINE
| ID: mdl-27172639
ABSTRACT
BACKGROUND:
Prolonged exposure to a selective progesterone receptor modulator (ulipristal acetate) in a patient with benign metastasizing leiomyoma did not result in endometrial hyperplasia or neoplasia. CASE A woman with history of benign metastasizing leiomyoma underwent medical treatment for 5 years with ulipristal acetate. Endometrial biopsies were performed at established intervals to monitor for intraepithelial neoplasia or progesterone receptor modulator-associated endometrial changes (PAECs). The patient tolerated UPA therapy well; there was no evidence of hyperplasia or proliferative changes associated with progesterone-associated endometrial changes.CONCLUSION:
In this case prolonged exposure to ulipristal acetate did not result in premalignant or malignant endometrial pathology.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Uterinas
/
Receptores de Progesterona
/
Endométrio
/
Leiomioma
/
Norpregnadienos
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article